Evidence map›Paper›PMID 39555359›Full record

ArticleIndian journal of surgical oncology2024

Hypercalcemic Ovarian Carcinoma (Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT)): A Case Series and Review of Literature of a Rare Malignancy.

Chandan C S, Abdul Waheed Mir, Ab Wahid Mir, Firdous Ahmad Dar, Syed Besina Yasin

Abstract read
In one paragraph

Article in Indian journal of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chandan C SDepartment of Surgical Oncology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, J&K India.ORCID 0009-0007-2286-4263
Abdul Waheed MirDepartment of Critical Care Medicine, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, J&K India.
Ab Wahid MirDepartment of Surgical Oncology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, J&K India.
Firdous Ahmad DarDepartment of Surgical Oncology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, J&K India.
Syed Besina YasinDepartment of Pathology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, J&K India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is one of the rare and aggressive cancers occurring mainly in adolescents and young women. It accounts for less than 0.01% of all ovarian malignancies, with around 500 cases reported to date in the medical literature. It has been postulated that these cases could be due to genetic alterations, and in 2014, studies discovered that SCCOHT is characterized by both germline and somatic deleterious mutations in SMARCA4. In this case series, we report two cases diagnosed with carcinoma ovary and found to be having mutations in SMARCA4. The patients in this case series were relatively young and both had germline SMARCA4 mutation. The first patient had FIGO stage IV disease and the second patient had FIGO stage III disease. The first patient started with paclitaxel plus carboplatin and the second patient started with gemcitabine plus docetaxel. One patient succumbed to disease within 1 year and another patient is alive at present with progression of disease. SCCOHT is very aggressive and needs diagnosis and treatment at an early stage. Early diagnosis and proper treatment may prolong survival. There is a need for evaluation of the possible role of targeted systemic therapeutic options as the conventional regimens are rarely sufficient.

Indexed as

HypercalcemiaOvarian carcinomaSCCOHTSMARCA4

Identifiers

PMID39555359
PMCPMC11564603

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.